Document is current
Any future updates will be listed below
-
Authors
Smith, Stacy R.
Esch, Robert E.
Nielsen, H. S.
Johnson, Sandra Marchese
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02393417 at ClinicalTrials.govDocuments that mention this clinical trial
Randomized Phase IIa Trial of Purified Candida Antigen for Common Warts: Evaluating the Safety and Efficacy Across Multiple Dosing Regimens
https://doi.org/10.1007/s13555-025-01387-1
-
Funding
Funding for this research was provided by:
Nielsen BioSciences, Inc
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 12 March 2025
First Online: 29 March 2025
Declarations
:
: Stacy R. Smith serves as a clinical study investigator for AbbVie, Alumnis, Amgen, Apollo Therapeutics, Caliway Biopharmaceuticals, Candesant Biomedical, Croma, Eli Lilly, Endo Pharmaceuticals, Evolus, Galderma, Janssen Research and Development, Moberg Pharma, Nielsen Biosciences, Pelage Pharmaceuticals, Pfizer, Q32Bio, Sofregen, Sun Pharmaceuticals, and Teoxane SA; is a consultant for AbbVie, Caliway Biopharmaceuticals, Candesant Biomedical, Eli Lilly, Evolus, Sofregen, and Teoxane SA; and, is a speaker for AbbVie, Eli Lilly, and Janssen Research and Development. H.S. Nielsen Jr. is the Founder, Vice Chairman of the Board of Directors, and employee of Nielsen BioSciences Inc. Robert E. Esch is a member of the Board of Directors of Nielsen BioSciences Inc. Sandra Marchese Johnson is a founder of Type IV Technologies; serves as a member of the advisory board for Arcutis; serves as a clinical study investigator for AbbVie, Amgen, Arcutis, BioMetrix, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Concert Pharmaceuticals, Dermavant Sciences, Evidera Galderma Research and Development, Incyte, Innovaderm Research, Janssen Pharmaceuticals, LEO Laboratories, Lily ICOS, National Psoriasis Foundation, Nielsen BioSciences, Novartis, Regeneron, Sanofi, Takeda Pharmaceuticals, TARGET Pharma, and the University of Pennsylvania; and is a speaker for Amgen, Arkansas College of Osteopathic Medicine, Dermavant Sciences, Galderma, Sanofi, and the University of Arkansas for Medical Sciences.
: This study was sponsored by Nielsen BioSciences and was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki (1964), including the current Seoul revision (2008), and that are consistent with Good Clinical Practice and applicable laws and regulations. The study was reviewed by an institutional review board (IRB), Institutional Review Board Services, on behalf of the study site prior to enrollment of participants. Informed consent was received from all participants prior to the initiation of study-related procedures.
